Ependymoma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Ependymoma – Pipeline Review, H2 2017’, provides an overview of the Ependymoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ependymoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ependymoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ependymoma

The report reviews pipeline therapeutics for Ependymoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ependymoma therapeutics and enlists all their major and minor projects

The report assesses Ependymoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ependymoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ependymoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ependymoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advantagene Inc

Amgen Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Cavion LLC

Celgene Corp

Eli Lilly and Company

Millennium Pharmaceuticals Inc

NewLink Genetics Corp

Ono Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ependymoma - Overview

Ependymoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Ependymoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ependymoma - Companies Involved in Therapeutics Development

Advantagene Inc

Amgen Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Cavion LLC

Celgene Corp

Eli Lilly and Company

Millennium Pharmaceuticals Inc

NewLink Genetics Corp

Ono Pharmaceutical Co Ltd

Ependymoma - Drug Profiles

abemaciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afatinib dimaleate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alisertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-207 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GliAtak - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

indoximod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ipilimumab + nivolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mibefradil dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nivolumab - Drug Profile

R&D Progress

pomalidomide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ependymoma - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Ependymoma, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Ependymoma – Pipeline by Advantagene Inc, H2 2017

Ependymoma – Pipeline by Amgen Inc, H2 2017

Ependymoma – Pipeline by Boehringer Ingelheim GmbH, H2 2017

Ependymoma – Pipeline by Bristol-Myers Squibb Company, H2 2017

Ependymoma – Pipeline by Cavion LLC, H2 2017

Ependymoma – Pipeline by Celgene Corp, H2 2017

Ependymoma – Pipeline by Eli Lilly and Company, H2 2017

Ependymoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Ependymoma – Pipeline by NewLink Genetics Corp, H2 2017

Ependymoma – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Ependymoma – Dormant Projects, H2 2017

List of Figures

List of Figures

Number of Products under Development for Ependymoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports